Display options
Cite
Amminger GP, Lin A, Kerr M, et al. Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Early Interv Psychiatry. 2021;doi: 10.1111/eip.13182.
Amminger, G. P., Lin, A., Kerr, M., Weller, A., Spark, J., Pugh, C., O'Callaghan, S., Berger, M., Clark, S. R., Scott, J. G., Baker, A., McGregor, I., Cotter, D., Sarnyai, Z., Thompson, A., Yung, A. R., O'Donoghue, B., Killackey, E., Mihalopoulos, C., Yuen, H. P., Nelson, B., & McGorry, P. D. (2021). Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Early intervention in psychiatry, . https://doi.org/10.1111/eip.13182
Amminger, G Paul, et al. "Cannabidiol for at risk for psychosis youth: A randomized controlled trial." Early intervention in psychiatry vol. (2021). doi: https://doi.org/10.1111/eip.13182
Amminger GP, Lin A, Kerr M, Weller A, Spark J, Pugh C, O'Callaghan S, Berger M, Clark SR, Scott JG, Baker A, McGregor I, Cotter D, Sarnyai Z, Thompson A, Yung AR, O'Donoghue B, Killackey E, Mihalopoulos C, Yuen HP, Nelson B, McGorry PD. Cannabidiol for at risk for psychosis youth: A randomized controlled trial. Early Interv Psychiatry. 2021 Jun 30; doi: 10.1111/eip.13182. Epub 2021 Jun 30. PMID: 34190422.
Copy Download .nbib Format: NLM
Share it on

Early Interv Psychiatry. 2021 Jun 30; doi: 10.1111/eip.13182. Epub 2021 Jun 30.

Cannabidiol for at risk for psychosis youth: A randomized controlled trial.

Early intervention in psychiatry

G Paul Amminger, Ashleigh Lin, Melissa Kerr, Amber Weller, Jessica Spark, Charlotte Pugh, Sally O'Callaghan, Maximus Berger, Scott R Clark, James G Scott, Andrea Baker, Iain McGregor, David Cotter, Zoltan Sarnyai, Andrew Thompson, Alison R Yung, Brian O'Donoghue, Eoin Killackey, Cathy Mihalopoulos, Hok Pan Yuen, Barnaby Nelson, Patrick D McGorry

Affiliations

  1. Orygen, Melbourne, Australia.
  2. The Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia.
  3. Telethon Kids Institute, The University of Western Australia, Perth, Australia.
  4. Discipline of Psychiatry, University of Adelaide, Adelaide, Australia.
  5. QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  6. Queensland Centre for Mental Health Research, The Park Centre for Mental Health, Brisbane, Australia.
  7. Metro North Mental Health Service, Herston, Australia.
  8. Lambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, Australia.
  9. Royal College of Surgeons, Dublin, Ireland.
  10. James Cook University, Townsville, Australia.
  11. School of Health Science, University of Manchester, Manchester, UK.
  12. Deakin University, Geelong, Australia.

PMID: 34190422 DOI: 10.1111/eip.13182

Abstract

BACKGROUND: No biological treatment has been firmly established for the at-risk stage of psychotic disorder. In this study we aim to test if subthreshold psychotic symptoms can be effectively treated with cannabidiol (CBD), a non-psychoactive compound of the plant Cannabis sativa. The question has taken on increased importance in the wake of evidence questioning both the need and efficacy of specific pharmacological interventions in the ultra-high risk (UHR) for psychosis group.

METHODS: Three-arm randomized controlled trial of 405 patients (135 per arm) aged 12-25 years who meet UHR for psychosis criteria. The study includes a 6-week lead-in phase during which 10% of UHR individuals are expected to experience symptom remission. Participants will receive CBD (per oral) at doses 600 or 1000 mg per day (fixed schedule) for 12 weeks. Participants in the third arm of the trial will receive matching placebo capsules. Primary outcome is severity of positive psychotic symptoms as measured by the Comprehensive Assessment of At-Risk Mental States at 12 weeks. We hypothesize that CBD will be significantly more effective than placebo in improving positive psychotic symptoms in UHR patients. All participants will also be followed up 6 months post baseline to evaluate if treatment effects are sustained.

CONCLUSION: This paper reports on the rationale and protocol of the Cannabidiol for At Risk for psychosis Youth (CanARY) study. This study will test CBD for the first time in the UHR phase of psychotic disorder.

© 2021 John Wiley & Sons Australia, Ltd.

Keywords: RCT; cannabidiol; psychosis; ultra-high risk; youth

References

  1. Addington, J., Epstein, I., Liu, L., French, P., Boydell, K. M., & Zipursky, R. B. (2011). A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophrenia Research, 125(1), 54-61. http://doi.org/10.1016/j.schres.2010.10.015 - PubMed
  2. Álvarez-Jiménez, M., Gleeson, J. F., Henry, L. P., Harrigan, S. M., Harris, M. G., Killackey, E., Bendall, S., Amminger, G. P., Yung, A. R., Herrman, H., Jackson, H. J., & McGorry, P. D. (2012). Road to full recovery: Longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychological Medicine, 42(3), 595-606. http://doi.org/10.1017/S0033291711001504 - PubMed
  3. Amminger, G. P., Berger, M., Rice, S. M., Davey, C. G., Schäfer, M. R., & McGorry, P. D. (2017). Novel biotherapies are needed in youth mental health. Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists, 25(2), 117-120. http://doi.org/10.1177/1039856217698237 - PubMed
  4. Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010). Long-chain -3 fatty acids for indicated prevention of psychotic disorders. Archives of General Psychiatry, 67(2), 146-154. http://doi.org/10.1001/archgenpsychiatry.2009.192 - PubMed
  5. Amminger, G. P., Schäfer, M. R., Schlögelhofer, M., Klier, C. M., & McGorry, P. D. (2015). Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications, 6, 7934. http://doi.org/10.1038/ncomms8934 - PubMed
  6. Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004). Causal association between cannabis and psychosis: Examination of the evidence. The British Journal of Psychiatry, 184, 110-117. - PubMed
  7. Bechdolf, A., Wagner, M., Ruhrmann, S., Harrigan, S., Putzfeld, V., Pukrop, R., Brockhaus-Dumke, A., Berning, J., Janssen, B., Decker, P., Bottlender, R., Maurer, K., Möller, H. J., Gaebel, W., Häfner, H., Maier, W., & Klosterkötter, J. (2012). Preventing progression to first-episode psychosis in early initial prodromal states. The British Journal of Psychiatry: The Journal of Mental Science, 200(1), 22-29. http://doi.org/10.1192/bjp.bp.109.066357 - PubMed
  8. Beck, K., Andreou, C., Studerus, E., Heitz, U., Ittig, S., Leanza, L., & Riecher-Rössler, A. (2019). Clinical and functional long-term outcome of patients at clinical high risk (CHR) for psychosis without transition to psychosis: A systematic review. Schizophrenia Research, 210C, 39-47. http://doi.org/10.1016/j.schres.2018.12.047 - PubMed
  9. Bergamaschi, M. M., Queiroz, R. H. C., Zuardi, A. W., & Crippa, J. A. S. (2011). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety, 6(4), 237-249. - PubMed
  10. Berk, M., Yucel, M., & McGorry, P. (2011). Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews, 35(3), 804-817. http://doi.org/10.1016/j.neubiorev.2010.10.001 - PubMed
  11. Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O'Carroll, C. M., Seal, M., Allen, P., Mehta, M. A., Stone, J. M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R. M., Zuardi, A. W., Crippa, J. A., Atakan, Z., & McGuire, P. K. (2010). Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology, 35(3), 764-774. http://doi.org/10.1038/npp.2009.184 - PubMed
  12. Bhattacharyya, S., Wilson, R., Appiah-Kusi, E., O'Neill, A., Brammer, M., Perez, J., Murray, R., Allen, P., Bossong, M. G., & McGuire, P. (2018). Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis. JAMA Psychiatry (Chicago, Ill.), 75, 1107-1117. http://doi.org/10.1001/jamapsychiatry.2018.2309 - PubMed
  13. Bitanihirwe, B. K. Y., & Woo, T.-U. W. (2011). Oxidative stress in schizophrenia: An integrated approach. Neuroscience and Biobehavioral Reviews, 35(3), 878-893. http://doi.org/10.1016/j.neubiorev.2010.10.008 - PubMed
  14. Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12(4), 825-836. http://doi.org/10.1007/s13311-015-0387-1 - PubMed
  15. Burstein, S. (2015). Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Bioorganic & Medicinal Chemistry, 23(7), 1377-1385. http://doi.org/10.1016/j.bmc.2015.01.059 - PubMed
  16. Calvert, M., Kyte, D., Mercieca-Bebber, R., Slade, A., Chan, A.-W., King, M. T., SPIRIT-PRO Group, Hunn, A., Bottomley, A., Regnault, A., Chan, A. W., Ells, C., O'Connor, D., Revicki, D., Patrick, D., Altman, D., Basch, E., Velikova, G., Price, G., … Groves, T. (2018). Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: The SPIRIT-PRO extension. JAMA: The Journal of the American Medical Association, 319(5), 483-494. http://doi.org/10.1001/jama.2017.21903 - PubMed
  17. Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017). Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Frontiers in Pharmacology, 8, 269. http://doi.org/10.3389/fphar.2017.00269 - PubMed
  18. Ceccarini, J., de Hert, M., van Winkel, R., Peuskens, J., Bormans, G., Kranaster, L., Enning, F., Koethe, D., Leweke, F. M., & van Laere, K. (2013). Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage, 79, 304-312. http://doi.org/10.1016/j.neuroimage.2013.04.052 - PubMed
  19. Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. (2020). Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology, 45, 1-8. http://doi.org/10.1038/s41386-020-0667-2 - PubMed
  20. Christensen, M. K., Lim, C. C. W., Saha, S., Plana-Ripoll, O., Cannon, D., Presley, F., Weye, N., Momen, N. C., Whiteford, H. A., Iburg, K. M., & McGrath, J. J. (2020). The cost of mental disorders: A systematic review. Epidemiology and Psychiatric Sciences, 29, e161. https://doi.org/10.1017/S204579602000075X - PubMed
  21. Cornblatt, B., Lencz, T., & Obuchowski, M. (2002). The schizophrenia prodrome: Treatment and high-risk perspectives. Schizophrenia Research, 54, 177-186. - PubMed
  22. Correll, C. U., Galling, B., Pawar, A., Krivko, A., Bonetto, C., Ruggeri, M., Craig, T. J., Nordentoft, M., Srihari, V. H., Guloksuz, S., Hui, C. L. M., Chen, E. Y. H., Valencia, M., Juarez, F., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., … Kane, J. M. (2018). Comparison of early intervention services vs treatment as usual for early-phase psychosis: A systematic review, meta-analysis, and meta-regression. JAMA Psychiatry (Chicago, Ill.), 75(6), 555-565. http://doi.org/10.1001/jamapsychiatry.2018.0623 - PubMed
  23. Davies, C., Cipriani, A., Ioannidis, J. P. A., Radua, J., Stahl, D., Provenzani, U., McGuire, P., & Fusar-Poli, P. (2018). Lack of evidence to favor specific preventive interventions in psychosis: A network meta-analysis. World Psychiatry, 17(2), 196-209. http://doi.org/10.1002/wps.20526 - PubMed
  24. Dodd, S., Maes, M., Anderson, G., Dean, O. M., Moylan, S., & Berk, M. (2013). Putative neuroprotective agents in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 42, 135-145. http://doi.org/10.1016/j.pnpbp.2012.11.007 - PubMed
  25. Early Psychosis Guidelines Writing Group, & EPPIC National Support Program. (2016). Australian clinical guidelines for early psychosis (2nd ed.). Orygen, The National Centre of Excellence in Youth Mental Health. - PubMed
  26. Egerton, A., Stone, J. M., Chaddock, C. A., Barker, G. J., Bonoldi, I., Howard, R. M., Merritt, K., Allen, P., Howes, O. D., Murray, R. M., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., & McGuire, P. K. (2014). Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology, 39(12), 2891-2899. http://doi.org/10.1038/npp.2014.143 - PubMed
  27. Farris, M. S., Shakeel, M. K., & Addington, J. (2020 May). Cannabis use in individuals at clinical high-risk for psychosis: A comprehensive review. Social Psychiatry and Psychiatric Epidemiology, 55(5), 527-537. https://doi.org/10.1007/s00127-019-01810-x - PubMed
  28. Fernández-Ruiz, J., Sagredo, O., Pazos, M. R., García, C., Pertwee, R., Mechoulam, R., & Martínez-Orgado, J. (2013). Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology, 75(2), 323-333. http://doi.org/10.1111/j.1365-2125.2012.04341.x - PubMed
  29. Fineberg, A. M., & Ellman, L. M. (2013). Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biological Psychiatry, 73(10), 951-966. http://doi.org/10.1016/j.biopsych.2013.01.001 - PubMed
  30. Flatow, J., Buckley, P., & Miller, B. J. (2013). Meta-analysis of oxidative stress in schizophrenia. Biological Psychiatry, 74(6), 400-409. http://doi.org/10.1016/j.biopsych.2013.03.018 - PubMed
  31. Foti, D. J., Kotov, R., Guey, L. T., & Bromet, E. J. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry, 167(8), 987-993. http://doi.org/10.1176/appi.ajp.2010.09020189 - PubMed
  32. Fraguas, D., Díaz-Caneja, C. M., Rodríguez-Quiroga, A., & Arango, C. (2017). Oxidative stress and inflammation in early onset first episode psychosis: A systematic review and meta-analysis. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 20(6), 435-444. http://doi.org/10.1093/ijnp/pyx015 - PubMed
  33. Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., Valmaggia, L., Cannon, T., Velthorst, E., de Haan, L., Cornblatt, B., Bonoldi, I., Birchwood, M., McGlashan, T., Carpenter, W., … Yung, A. (2013). The psychosis high-risk state: A comprehensive state-of-the-art review. JAMA Psychiatry (Chicago, Ill.), 70(1), 107-120. http://doi.org/10.1001/jamapsychiatry.2013.269 - PubMed
  34. Fusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O'Carrol, C., Atakan, Z., Zuardi, A. W., & McGuire, P. K. (2009). Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry, 66(1), 95-105. http://doi.org/10.1001/archgenpsychiatry.2008.519 - PubMed
  35. Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkötter, J., & Piomelli, D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 29(11), 2108-2114. http://doi.org/10.1038/sj.npp.1300558 - PubMed
  36. Hager, B. M., & Keshavan, M. S. (2015). Neuroimaging biomarkers for psychosis. Current Behavioral Neuroscience Reports, 2015, 1-10. - PubMed
  37. Hallak, J. E. C., Dursun, S. M., Bosi, D. C., de Macedo, L. R. H., Machado-de-Sousa, J. P., Abrão, J., Crippa, J. A. S., McGuire, P., Krystal, J. H., Baker, G. B., & Zuardi, A. W. (2011). The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 35(1), 198-202. http://doi.org/10.1016/j.pnpbp.2010.11.002 - PubMed
  38. Henry, L. P., Amminger, G. P., Harris, M. G., Yuen, H. P., Harrigan, S. M., Prosser, A. L., Schwartz, O. S., Farrelly, S. E., Herrman, H., Jackson, H. J., & McGorry, P. D. (2010). The EPPIC follow-up study of first-episode psychosis: Longer-term clinical and functional outcome 7 years after index admission. The Journal of Clinical Psychiatry, 71(6), 716-728. http://doi.org/10.4088/JCP.08m04846yel - PubMed
  39. Hurd, Y. L. (2017). Cannabidiol: Swinging the marijuana pendulum from “weed” to medication to treat the opioid epidemic. Trends in Neurosciences, 40(3), 124-127. http://doi.org/10.1016/j.tins.2016.12.006 - PubMed
  40. Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, 2(1), 139-154. http://doi.org/10.1089/can.2016.0034 - PubMed
  41. Insel, T. R. (2010). Rethinking schizophrenia. Nature, 468(7321), 187-193. http://doi.org/10.1038/nature09552 - PubMed
  42. Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162(1-3), 153-161. http://doi.org/10.1016/j.schres.2015.01.033 - PubMed
  43. Jalbrzikowski, M., Freedman, D., Hegarty, C. E., Mennigen, E., Karlsgodt, K. H., Olde Loohuis, L. M., Ophoff, R. A., Gur, R. E., & Bearden, C. E. (2019). Structural brain alterations in youth with psychosis and bipolar spectrum symptoms. Journal of the American Academy of Child & Adolescent Psychiatry, 58(11), 1079-1091. https://doi.org/10.1016/j.jaac.2018.11.012 - PubMed
  44. Kaur, T., & Cadenhead, K. S. (2010). Treatment implications of the schizophrenia prodrome. Current Topics in Behavioral Neurosciences, 4, 97-121. - PubMed
  45. Kirkpatrick, B., & Miller, B. J. (2013). Inflammation and schizophrenia. Schizophrenia Bulletin, 39(6), 1174-1179. http://doi.org/10.1093/schbul/sbt141 - PubMed
  46. Koethe, D., Giuffrida, A., Schreiber, D., Hellmich, M., Schultze-Lutter, F., Ruhrmann, S., Klosterkötter, J., Piomelli, D., & Leweke, F. M. (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. The British Journal of Psychiatry: The Journal of Mental Science, 194(4), 371-372. http://doi.org/10.1192/bjp.bp.108.053843 - PubMed
  47. Lavoie, S., Berger, M., Schlögelhofer, M., Schäfer, M. R., Rice, S., Kim, S. W., Hesse, J., McGorry, P. D., Smesny, S., & Amminger, G. P. (2017). Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Translational Psychiatry, 7(3), e1064. http://doi.org/10.1038/tp.2017.30 - PubMed
  48. Leweke, F. M. (2012). Anandamide dysfunction in prodromal and established psychosis. Current Pharmaceutical Design, 18(32), 5188-5193. - PubMed
  49. Leweke, F. M., & Koethe, D. (2008). Cannabis and psychiatric disorders: It is not only addiction. Addiction Biology, 13(2), 264-275. http://doi.org/10.1111/j.1369-1600.2008.00106.x - PubMed
  50. Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport, 10(8), 1665-1669. - PubMed
  51. Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C. (2016). Therapeutic potential of cannabinoids in psychosis. Biological Psychiatry, 79(7), 604-612. http://doi.org/10.1016/j.biopsych.2015.11.018 - PubMed
  52. Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, e94. http://doi.org/10.1038/tp.2012.15 - PubMed
  53. Lin, A., Wood, S. J., Nelson, B., Beavan, A., McGorry, P., & Yung, A. R. (2015). Outcomes of nontransitioned cases in a sample at ultra-high risk for psychosis. American Journal of Psychiatry, 172(3), 249-258. http://doi.org/10.1176/appi.ajp.2014.13030418 - PubMed
  54. Markulev, C., McGorry, P. D., Nelson, B., Yuen, H. P., Schaefer, M., Yung, A. R., Thompson, A., Berger, G., Mossaheb, N., Schlögelhofer, M., Smesny, S., de Haan, L., Riecher-Rössler, A., Nordentoft, M., Chen, E. Y. H., Verma, S., Hickie, I., & Amminger, G. P. (2015). NEURAPRO-E study protocol: A multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Early Intervention in Psychiatry, 11, 418-428. http://doi.org/10.1111/eip.12260 - PubMed
  55. Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Archives of General Psychiatry, 62(9), 975-983. http://doi.org/10.1001/archpsyc.62.9.975 - PubMed
  56. McGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., Hawkins, K. A., Hoffman, R. E., Preda, A., Epstein, I., Addington, D., Lindborg, S., Trzaskoma, Q., Tohen, M., & Breier, A. (2006). Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. The American Journal of Psychiatry, 163(5), 790-799. http://doi.org/10.1176/appi.ajp.163.5.790 - PubMed
  57. McGorry, P. D. (2010). Staging in neuropsychiatry: A heuristic model for understanding, prevention and treatment. Neurotoxicity Research, 18(3-4), 244-255. http://doi.org/10.1007/s12640-010-9179-x - PubMed
  58. McGorry, P. D. (2014). Beyond psychosis risk: Early clinical phenotypes in mental disorder and the subthreshold pathway to safe, timely and effective care. Psychopathology, 47(5), 285-286. http://doi.org/10.1159/000365308 - PubMed
  59. McGorry, P. D., Goldstone, S. D., Parker, A. G., Rickwood, D. J., & Hickie, I. B. (2014). Cultures for mental health care of young people: An Australian blueprint for reform. The Lancet. Psychiatry, 1(7), 559-568. http://doi.org/10.1016/S2215-0366(14)00082-0 - PubMed
  60. McGorry, P. D., Killackey, E., & Yung, A. (2008). Early intervention in psychosis: Concepts, evidence and future directions. World Psychiatry: Official Journal of the World Psychiatric Association (WPA), 7(3), 148-156. - PubMed
  61. McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G. E., Chen, E. Y. H., de Haan, L., Nieman, D. H., Nordentoft, M., Riecher-Rössler, A., Verma, S., Thompson, A., Yung, A. R., & Amminger, G. P. (2017). Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: The NEURAPRO randomized clinical trial. JAMA Psychiatry (Chicago, Ill.), 74(1), 19-27. http://doi.org/10.1001/jamapsychiatry.2016.2902 - PubMed
  62. McGorry, P., Yung, A., Phillips, L., Yuen, H., Francey, S., Cosgrave, E., Germano, D., Bravin, J., McDonald, T., Blair, A., Adlard, S., & Jackson, H. (2002). Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry, 59(10), 921-928. - PubMed
  63. McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., Taylor, A., & Wright, S. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225-231. http://doi.org/10.1176/appi.ajp.2017.17030325 - PubMed
  64. Mei, C., van der Gaag, M., Nelson, B., Smit, F., Yuen, H. P., Berger, M., Krcmar, M., French, P., Amminger, G. P., Bechdolf, A., Cuijpers, P., Yung, A. R., & McGorry, P. D. (2021). Preventive interventions for individuals at ultra high risk for psychosis: An updated and extended meta-analysis. Clinical Psychology Review, 86, 102005. https://doi.org/10.1016/j.cpr.2021.102005 - PubMed
  65. Miller, B. J., Buckley, P., Seabolt, W., Mellor, A., & Kirkpatrick, B. (2011). Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects. Biological Psychiatry, 70(7), 663-671. http://doi.org/10.1016/j.biopsych.2011.04.013 - PubMed
  66. Mongan, D., Ramesar, M., Föcking, M., Cannon, M., & Cotter, D. (2020). Role of inflammation in the pathogenesis of schizophrenia: A review of the evidence, proposed mechanisms and implications for treatment. Early Intervention in Psychiatry, 14(4), 385-397. http://doi.org/10.1111/eip.12859 - PubMed
  67. Moore, T. H. M., Zammit, S., Lingford-Hughes, A., Barnes, T. R. E., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet, 370(9584), 319-328. http://doi.org/10.1016/S0140-6736(07)61162-3 - PubMed
  68. Morrison, A. P., French, P., Stewart, S. L. K., Birchwood, M., Fowler, D., Gumley, A. I., Jones, P. B., Bentall, R. P., Lewis, S. W., Murray, G. K., Patterson, P., Brunet, K., Conroy, J., Parker, S., Reilly, T., Byrne, R., Davies, L. M., & Dunn, G. (2012). Early detection and intervention evaluation for people at risk of psychosis: Multisite randomised controlled trial. BMJ (Clinical Research Ed), 344, e2233-e2233. http://doi.org/10.1136/bmj.e2233 - PubMed
  69. National Institute for Health and Care Excellence (NICE). (2016). Clinical Guideline Number 155. Psychosis and schizophrenia in children and young people: Recognition and management. Published by The British Psychological Society and The Royal College of Psychiatrists. https://www.nice.org.uk/guidance/cg155 - PubMed
  70. Nelson, B., Amminger, G. P., Yuen, H. P., Wallis, N., J Kerr, M., Dixon, L., Carter, C., Loewy, R., Niendam, T. A., Shumway, M., Morris, S., Blasioli, J., & McGorry, P. (2017). Staged treatment in early psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Early Intervention in Psychiatry, 12, 292-306. http://doi.org/10.1111/eip.12459 - PubMed
  71. Nelson, B., McGorry, P. D., Wichers, M., Wigman, J. T. W., & Hartmann, J. A. (2017). Moving from static to dynamic models of the onset of mental disorder: A review. JAMA Psychiatry (Chicago, Ill.), 74(5), 528-534. http://doi.org/10.1001/jamapsychiatry.2017.0001 - PubMed
  72. Nelson, B., Yuen, H. P., Wood, S. J., Lin, A., Spiliotacopoulos, D., Bruxner, A., Broussard, C., Simmons, M., Foley, D. L., Brewer, W. J., Francey, S. M., Amminger, G. P., Thompson, A., McGorry, P. D., & Yung, A. R. (2013). Long-term follow-up of a group at ultra high risk (“prodromal”) for psychosis: The PACE 400 study. JAMA Psychiatry (Chicago, Ill.), 70(8), 793-802. http://doi.org/10.1001/jamapsychiatry.2013.1270 - PubMed
  73. Nelson, B., Yuen, H.-P., Lin, A., Wood, S. J., McGorry, P. D., Hartmann, J. A., & Yung, A. R. (2016). Further examination of the reducing transition rate in ultra high risk for psychosis samples: The possible role of earlier intervention. Schizophrenia Research, 174(1-3), 43-49. http://doi.org/10.1016/j.schres.2016.04.040 - PubMed
  74. Nordentoft, M., Petersen, L., Jeppesen, P., Thorup, A. A. E., Abel, M.-B. H., Ohlenschlaeger, J., Christensen, T. Ø., Krarup, G., & Jørgensen, P. (2006). OPUS: A randomised multicenter trial of integrated versus standard treatment for patients with a first-episode psychosis-Secondary publication. Ugeskrift for Laeger, 168(4), 381-384. - PubMed
  75. Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389-462. http://doi.org/10.1124/pr.58.3.2 - PubMed
  76. Perkins, D. O., Jeffries, C. D., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., Seidman, L. J., Tsuang, M. T., Walker, E. F., Woods, S. W., & Heinssen, R. (2014). Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: Preliminary results from the NAPLS project. Schizophrenia Bulletin, 41, 419-428. http://doi.org/10.1093/schbul/sbu099 - PubMed
  77. Rais, M., Cahn, W., Van Haren, N., Schnack, H., Caspers, E., Hulshoff Pol, H., & Kahn, R. (2008). Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. The American Journal of Psychiatry, 165(4), 490-496. http://doi.org/10.1176/appi.ajp.2007.07071110 - PubMed
  78. Rajan, T. S., Giacoppo, S., Iori, R., de Nicola, G. R., Grassi, G., Pollastro, F., Bramanti, P., & Mazzon, E. (2016). Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. Fitoterapia, 112, 104-115. http://doi.org/10.1016/j.fitote.2016.05.008 - PubMed
  79. Renard, J., Norris, C., Rushlow, W., & Laviolette, S. R. (2017). Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments. Neuroscience and Biobehavioral Reviews, 75, 157-165. http://doi.org/10.1016/j.neubiorev.2017.02.006 - PubMed
  80. Sachs, J., McGlade, E., & Yurgelun-Todd, D. (2015). Safety and toxicology of cannabinoids. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 12(4), 735-746. http://doi.org/10.3109/00952990.2014.894047 - PubMed
  81. Sales, A. J., Crestani, C. C., Guimaraes, F. S., & Joca, S. R. L. (2018). Antidepressant-like effect induced by cannabidiol is dependent on brain serotonin levels. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 86, 255-261. http://doi.org/10.1016/j.pnpbp.2018.06.002 - PubMed
  82. Schulz, K. F., Altman, D. G., Moher, D., & CONSORT Group. (2010). CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. Trials, 11, 32. http://doi.org/10.1186/1745-6215-11-32 - PubMed
  83. van der Gaag, M., Smit, F., Bechdolf, A., French, P., Linszen, D. H., Yung, A. R., McGorry, P., & Cuijpers, P. (2013). Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophrenia Research, 149(1-3), 56-62. http://doi.org/10.1016/j.schres.2013.07.004 - PubMed
  84. Veen, N. D., Selten, J.-P., van der Tweel, I., Feller, W. G., Hoek, H. W., & Kahn, R. S. (2004). Cannabis use and age at onset of schizophrenia. The American Journal of Psychiatry, 161(3), 501-506. - PubMed
  85. Wong, D. F., Kuwabara, H., Horti, A. G., Raymont, V., Brasic, J., Guevara, M., Ye, W., Dannals, R. F., Ravert, H. T., Nandi, A., Rahmim, A., Ming, J. E., Grachev, I., Roy, C., & Cascella, N. (2010). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. NeuroImage, 52(4), 1505-1513. http://doi.org/10.1016/j.neuroimage.2010.04.034 - PubMed
  86. Yung, A. R., & McGorry, P. D. (1996). The prodromal phase of first-episode psychosis: Past and current conceptualizations. Schizophrenia Bulletin, 22(2), 353-370. - PubMed
  87. Yung, A. R., McGorry, P. D., McFarlane, C. A., Jackson, H. J., Patton, G. C., & Rakkar, A. (1996). Monitoring and care of young people at incipient risk of psychosis. Schizophrenia Bulletin, 22(2), 283-303. - PubMed
  88. Yung, A. R., Phillips, L. J., McGorry, P. D., McFarlane, C. A., Francey, S., Harrigan, S., Patton, G. C., & Jackson, H. J. (1998). Prediction of psychosis. A step towards indicated prevention of schizophrenia. The British Journal of Psychiatry. Supplement, 172(33), 14-20. - PubMed
  89. Yung, A. R., Yuen, H. P., McGorry, P. D., Phillips, L. J., Kelly, D., Dell'Olio, M., Francey, S. M., Cosgrave, E. M., Killackey, E., Stanford, C., Godfrey, K., & Buckby, J. (2005). Mapping the onset of psychosis: The Comprehensive Assessment of At-Risk Mental States. The Australian and New Zealand Journal of Psychiatry, 39(11-12), 964-971. http://doi.org/10.1111/j.1440-1614.2005.01714.x - PubMed
  90. Zeidler, J., Slawik, L., Fleischmann, J., & Greiner, W. (2012). The costs of schizophrenia and predictors of hospitalisation from the statutory health insurance perspective. Health Economics Review, 2(1), 9. http://doi.org/10.1186/2191-1991-2-9 - PubMed
  91. Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design, 18(32), 5131-5140. - PubMed
  92. Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of Psychopharmacology (Oxford, England), 20(5), 683-686. http://doi.org/10.1177/0269881106060967 - PubMed
  93. Zuardi, A. W., Morais, S. L., Guimarães, F. S., & Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. The Journal of Clinical Psychiatry, 56(10), 485-486. - PubMed

Publication Types

Grant support